USD10
IKT azioni
Informazioni su Inhibikase TherapeuticsInhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
USD10
IKT azioni
Informazioni su Inhibikase TherapeuticsInhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
Dati insufficienti
Capitalizzazione di mercato
218,28 Mln USD
PREZZO DI APERTURA
1,84 USD
MINIMO (1 anno)
1,33 USD
MASSIMO (1 anno)
2,46 USD
MINIMO (24H)
1,78 USD
MASSIMO (24 ore)
1,88 USD
VOLUME (24 ore)
8,87 Mln USD
737,51%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | 1,84 USD | |
1 giorno | 1,83 USD | |
1 settimana | 2,05 USD |